AltPlus Holdings Inc.
Notice Regarding Change in Use of Proceeds for the 9th and 10th Series Stock Acquisition Rights by Third-Party Allotment and the 11th Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) and the 12th Series Stock Acquisition Rights
Changed the intended use of funds raised via stock acquisition rights. Net proceeds from the 9th–10th series totaled 1,006 million yen, mainly allocated to new title development funding. The 11th–12th series were acquired and cancelled, and remaining amounts were reallocated to M&A funds and crypto asset business funding. Spending period extended to September 2027; impact on future performance is under review.
Key Figures
- Funding for development and operation of new titles: 967 million yen
- Funding for securing development personnel: 38 million yen
- Total allocation due to acquisition and cancellation of the 11th and 12th series stock acquisition rights: 612 million yen (allocated)
AI要約
Overview of Change in Capital Policy
At the board meeting held today, we decided to change the use of proceeds for stock acquisition rights issued by third-party allotment. Net proceeds from the 9th and 10th series stock acquisition rights were confirmed at 1,006 million yen, and the entire amount is planned to be allocated to (1) funding for the development and operation of new titles. In addition, the required amount for (1) is 1,262 million yen, and the shortfall of 294 million yen will be covered by this fundraising. As of October 31, 2026, 768 million yen has been allocated.
Acquisition and Cancellation of the 11th and 12th Series Stock Acquisition Rights and Future Allocations
Regarding the 11th and 12th series stock acquisition rights, we resolved to acquire and cancel the remaining portions. Since the funds raised fell short of the original plan, we revised the allocation plan to apply funds to M&A financing (Okazaki Holdings), other M&A funds, and funding for the crypto asset business. The allocation period is extended until September 2027.
AltPlus Holdings Inc.
Company overview · Stock price · Financial data · All IR
